

## References

### Pharmacogenetic (PGx) Testing to Improve Patient Mental Health Outcomes During a Pandemic

Page 8–9

1. Xiang YT, Yang Y, Li W, et al. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. *Lancet Psychiatry*. 2020;7(3):228–229
2. Yang Y, Li W, Zhang Q, Zhang L, Cheung T, Xiang YT. Mental health services for older adults in China during the COVID-19 outbreak. *Lancet Psychiatry*. 2020;7(4)
3. Neria Y, Nandi A, Galea S. Post-traumatic stress disorder following disasters: a systematic review. *Psychol Med*. 2008;38(4):467–480
4. Lee AM, Wong JG, McAlonan GM, et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. *Can J Psychiatry*. 2007;52(4):233–240
5. <https://www.ctvnews.ca/video?clipId=1937943>
6. <https://www.ctvnews.ca/health/coronavirus/calls-to-distress-lines-jump-as-covid-19-sparks-dislocation-and-anxiety-1.4855047>
7. <https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/managing-stress-anxiety.html>
8. Cohen, G.H. et al.: Comparison of simulated treatment and cost-effectiveness of a stepped care case-finding intervention vs usual care for posttraumatic stress disorder after a natural disaster. *JAMA Psychiatry*. 2017;74(12):1251–1258.
9. Smetanin et al. (2011). The life and economic impact of major mental illnesses in Canada: 2011–2041. Prepared for the Mental Health Commission of Canada. Toronto: RiskAnalytica
10. Crisafulli C, Fabbri C, Porcelli S et al. Pharmacogenetics of Antidepressants. *Front. Pharmacol*. 2,6 (2011)
11. Bush WS, Crosslin DR, Owusu-Obeng A, et al. Genetic variation among 82 pharmacogenes: the PGRNseq data from the eMERGE network. *Clin Pharmacol Ther*. 2016;100(2):160–169
12. Ji Y, Skierka JM, Blommel JH, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. *J Mol Diagn*. 2016;18(3):438–445.
13. Van Driest SL et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. *Clin Pharmacol Ther*. 2014;95(4):423–431
14. Kalow W, Tang BK, Endrenyi I. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. *Pharmacogenetics*. 1998;8:283–9
15. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. *N Engl J Med* 2011; 364: 1144–1153
16. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: implications for clinical practice. *Am J Psychiatry*. 2006;163:28–40
17. Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. *J Clin Psychopharmacol*. 2011;31:512–516
18. Rush A.J. et al.: Acute and longer term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\*D report. *Am. J. Psychiatry* 163(11), 1905–1917 (2006)
19. Thase M.E. et al.: Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. *Int. Clin. Psychopharmacol*. 25(4), 189–198 (2010)
20. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: implications for clinical practice. *Am J Psychiatry*. 2006;163:28–40
21. Huynh NN, McIntyre RS. What are the implications of the STAR\*D Trial for primary care? A review and synthesis. *Prim Care Companion J Clin Psychiatry*. 2008;10(2):91–96. 17. Mental Health Care Health Professional
22. Brown MT et al. Medication adherence – WHO cares? *Mayo Clin Proc*. 2011 Apr; 86(4): 304–314
23. <https://www.thepharmaletter.com/article/psychiatric-conditions-set-to-rise-due-to-covid-19>
24. Gredin, John et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. *Journal of Psychiatric Research*. 2019; 111: 59–67
25. Hall – Flavin et al. Using a pharmacogenomic algorithm to guide the treatment of depression. *Transl Psychiatry*. 2012; Oct; 2 (10)
26. Winner J et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. *Current Medical Research & Opinion*. volume 31, 2015 – Issue 9, Pages 1633–1643
27. Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. *Transl Psychiatry*. 2013;3:e242.
28. Bousman, C.A., Zierhut, H. & Müller, D.J. Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection. *Clin. Pharmacol. Ther*. 106, 309–312 (2019)
29. Dewa, Chau, and Dermer (2010). Examining the comparative incidence and costs of physical and mental health-related disabilities in an employed population. *Journal of Occupational and Environmental Medicine*, 52: 758–62. Number of disability cases calculated using Statistics Canada employment data, retrieved from <http://www40.statcan.ca/101/cst01/labor21a-eng.htm>.

# COVID-19 and Vulnerable Populations

## Page 10

1. World Health Organization. Q&A on coronaviruses (COVID-19). Last updated 2020 April 17 [Internet, cited 2020 July 8]. Available from: <https://www.who.int/news-room/q-a-detail/q-a-coronaviruses>
2. The Lancet Editorial. Redefining vulnerability in the era of COVID-19. *The Lancet*. Vol 395. Published 2020 April 4 [Internet, cited 2020 April 14]. Available from: [https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(20\)30757-1.pdf](https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30757-1.pdf)
3. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): People who are at increased risk for severe illness. Last updated 2020 June 25 [Internet, cited 2020 July 8]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-increased-risk.html>
4. Government of Canada, Public Health Agency of Canada. Coronavirus Disease (COVID-19): Vulnerable Populations and COVID-19. Last updated 2020 June 19 [Internet, cited 2020 July 8]. Available from: <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/vulnerable-populations-covid-19.html>
5. Government of Canada, Public Health Agency of Canada. Coronavirus Disease 2019 (COVID-19): Epidemiology update. Last updated 2020 July 12 [Internet, cited 2020 July 13]. Available from: <https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html>
6. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR*. 2020 April 8. Vol 69 [cited 2020 April 14]. Available from: <https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6915e3-H.pdf>
7. Government of Canada, Public Health Agency of Canada. COVID-19 signs, symptoms and severity of disease: A clinician guide. Last updated 2020 June 18 [Internet, cited 2020 July 11]. Available from: <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html>
8. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *International Journal of Infectious Diseases* 94 (2020) 91-95. Available from: <https://doi.org/10.1016/j.ijid.2020.03.017>
9. Gasmí A, Noor S, Tippairote T, et al. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. *Clinical Immunology* 215 (2020) 108409. Available from: <https://doi.org/10.1016/j.clim.2020.108409>
10. Patwardhan P. COVID-19: Risk of increase in smoking rates among England's 6 million smokers and relapse among England's 11 million ex-smokers. *BJGP Open*. 2020 April 8. doi: 10.3399/bjgpopen20X101067

# Pregnancy and Breastfeeding During the COVID-19 Pandemic

## Page 15

1. The Society of Obstetricians and Gynecologists of Canada [SOGC]. SOGC Statement on Pregnant Workers during the COVID-19 Pandemic. 2020 May 21 [Internet]. Ottawa, ON [cited 2020 July 8]. Available from: <https://sogc.org/en/content/featured-news/SOGC-Statement-on-Pregnant-Workers-during-the-COVID-19-Pandemic.aspx>
2. The Society of Obstetricians and Gynecologists of Canada [SOGC]. Revised SOGC Infectious Disease Committee Statement on Health Care Workers during the COVID-19 Pandemic. 2020 March 27 [Internet]. Ottawa, ON [cited 2020 July 8]. Available from: <https://www.sogc.org/en/content/featured-news/SOGC-Infectious-Disease-Committee-Statement-on-Health-Care-Workers-during-COVID19Pandemic.aspx>
3. The Society of Obstetricians and Gynecologists of Canada [SOGC]. Updated SOGC Committee Opinion - COVID-19 in Pregnancy. 2020 March 13 [Internet]. Ottawa, ON [cited 2020 July 8]. Available from: [https://www.sogc.org/en/content/featured-news/Updated-SOGC-Committee-Opinion\\_\\_COVID-19-in-Pregnancy.aspx](https://www.sogc.org/en/content/featured-news/Updated-SOGC-Committee-Opinion__COVID-19-in-Pregnancy.aspx)
4. Lingkong A, Xia S, Wenhao Y, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. *JAMA-Pediatrics*. (2020 March 26). Available from: <http://doi:10.1001/jamapediatrics.2020.0878>
5. Aggarwal V, Essalah A, Arwini B, et al. COVID-19 in Pregnancy. *OBGYN Academy*. Revised 2020 May 4 [Internet, cited 2020 July 8]. Available from: <https://obgynacademy.com/covid-19>
6. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): Pregnancy & Breastfeeding. Last reviewed 2020 June 25 [Internet, cited 2020 July 8]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html>

# COVID-19 in the Paediatric Population

## Page 16

1. Rasmussen SA, Thompson LA. Coronavirus Disease 2019 and Children: What Pediatric Health Care Clinicians Need to Know. *JAMA Pediatr*. 2020 Apr 3.
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020 Feb 24. doi: 10.1001/jama.2020.2648.
3. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. *Pediatrics*. 2020; doi: 10.1542/peds.2020-0702
4. Coronavirus Disease 2019 (COVID-19): Epidemiology update. Government of Canada, Public Health Agency of Canada. Last updated July 14, 2020. Accessed July 14, 2020. <<https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html>>
5. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. World Health Organization. Accessed July 10, 2020. <<https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>>
6. Paediatric inflammatory multisystem syndrome temporally associated with COVID-19. Canadian Paediatric Society. Accessed July 10, 2020. <<https://www.cps.ca/en/documents/position/pims>>
7. Milstone A. Coronavirus in Babies and Children. *John Hopkins Medicine*. Accessed July 10, 2020. <<https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-in-babies-and-children>>
8. How to care for a child with COVID-19 at home: Advice for caregivers. Health Canada. Accessed July 10, 2020. <<https://www.canada.ca/en/public-health/services/publications/diseases-conditions/how-to-care-for-child-with-covid-19-at-home-advice-for-caregivers.html>>
9. Coronavirus Disease 2019 (COVID-19) Frequently Asked Questions. Centers for Disease Control and Prevention. Accessed July 10, 2020. <<https://www.cdc.gov/coronavirus/2019-ncov/faq.html#covid19-children>>
10. Coronavirus Disease 2019 (COVID-19) Talking to Children. Centers for Disease Control and Prevention. Accessed July 10, 2020. <<https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/talking-with-children.html>>

# Helping Your Asthma Patients Get Enough Air – The Pivotal Role of the Pharmacist

Page 18–20

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Published online 2020. Accessed May 8, 2020. [www.ginasthma.org](http://www.ginasthma.org)
2. O'Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? *Eur Respir J*. 2017;50(3). doi:10.1183/13993003.01103-2017
3. Beasley R, Bird G, Harper J, Weatherall M. The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity. *Eur Respir J*. 2018;52(5). doi:10.1183/13993003.00694-2018
4. Hull SA, McKibben S, Homer K, Taylor SJ, Pike K, Griffiths C. Asthma prescribing, ethnicity and risk of hospital admission: an analysis of 35,864 linked primary and secondary care records in East London. *NPJ Prim Care Respir Med*. 2016;26:16049. doi:10.1038/nnpjcrm.2016.49
5. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. *Am J Respir Crit Care Med*. 1994;149(3 Pt 1):604-610. doi:10.1164/ajrccm.149.3.8118625
6. Royal College of Physicians. Why asthma still kills. RCP London. Published August 11, 2015. Accessed July 19, 2019. <https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills>
7. Cole S, Seale C, Griffiths C. "The blue one takes a battering" why do young adults with asthma overuse bronchodilator inhalers? A qualitative study. *BMJ Open*. 2013;3(2). doi:10.1136/bmjopen-2012-002247
8. Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. *Am J Respir Crit Care Med*. 2010;181(6):566-577. doi:10.1164/rccm.200906-0907OC
9. Gauvreau GM, Jordana M, Watson RM, Cockcroft DW, O'Byrne PM. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. *Am J Respir Crit Care Med*. 1997;156(6):1738-1745. doi:10.1164/ajrccm.156.6.96-08042
10. Lohse MJ, Benovic JL, Caron MG, Lefkowitz RJ. Multiple pathways of rapid beta 2-adrenergic receptor desensitization. Delineation with specific inhibitors. *J Biol Chem*. 1990;265(6):3202-3211.
11. Johnston SL, Edwards MR. Mechanisms of adverse effects of (beta)-agonists in asthma. *Thorax*. 2009;64(9):739-741. doi:10.1136/thx.2009.119230
12. Chapman KR, Verbeek PR, White JG, Rebeck AS. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. *N Engl J Med*. 1991;324(12):788-794. doi:10.1056/NEJM199103213241202
13. Asthma Society of Canada. Severe Asthma: The Canadian Patient Journey. Published online 2014. Accessed September 28, 2018. <https://www.asthma.ca/wp-content/uploads/2017/06/SAstudy.pdf>
14. Sadatsafavi M, Rousseau R, Chen W, Zhang W, Lynd L, FitzGerald JM. The preventable burden of productivity loss due to suboptimal asthma control: a population-based study. *Chest*. 2014;145(4):787-793. doi:10.1378/chest.13-1619
15. Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. *Allergy*. 2019;74(2):273-283. doi:10.1111/all.13556
16. Janson C, Lisspers K, Stållberg B, et al. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR). *Respir Res*. 2018;19(1):168. doi:10.1186/s12931-018-0855-3
17. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Published online 2019. [www.ginasthma.org](http://www.ginasthma.org)
18. Kaplan A, Mitchell PD, Cave AJ, Gagnon R, Foran V, Ellis AK. Effective Asthma Management: Is It Time to Let the AIR out of SABA? *J Clin Med*. 2020;9(4). doi:10.3390/jcm9040921
19. Sears MR, Boulet L-P, Laviolette M, et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. *Eur Respir J*. 2008;31(5):982-989. doi:10.1183/09031936.00104007
20. Bateman ED, Reddel HK, O'Byrne PM, et al. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. *N Engl J Med*. 2018;378(20):1877-1887. doi:10.1056/NEJMoal715275
21. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. *New England Journal of Medicine*. Published online May 16, 2018. doi:10.1056/NEJMoal715274
22. Licskai C, Yang CL, Lemiere C, et al. Are the 2019 Global Initiative for Asthma (GINA) strategy recommendations applicable to the Canadian context? *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*. 2019;0(0):1-4. doi:10.1080/24745332.2019.1679553
23. Loughheed MD, Lemiere C, Ducharme FM, et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. *Can Respir J*. 2012;19(2):127-164.
24. Engelkes M, Janssens HM, Jongste JC de, Sturkenboom MCJM, Verhamme KMC. Medication adherence and the risk of severe asthma exacerbations: a systematic review. *European Respiratory Journal*. 2015;45(2):396-407. doi:10.1183/09031936.00075614
25. Fiore M, Jaén C, Baker T. Treating Tobacco Use and Dependence: 2008 Update. Published online May 2008.
26. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol*. 2004;113(1):59-65. doi:10.1016/j.jaci.2003.09.008
27. Bosnic-Anticevich SZ, Cvetkovski B, Azzi EA, Srour P, Tan R, Kritikos V. Identifying Critical Errors: Addressing Inhaler Technique in the Context of Asthma Management. *Pulm Ther*. 2018;4(1):1-12. doi:10.1007/s41030-018-0051-0
28. Attar-Zadeh CP 1 F 2019By D. UK asthma mortality is too high, but pharmacy can help. *Pharmaceutical Journal*. Accessed October 4, 2019. <https://www.pharmaceutical-journal.com/opinion/insight/uk-asthma-mortality-is-too-high-but-pharmacy-can-help/20206055.article>
29. National Health Service. The NHS Long Term Plan. NHS Long Term Plan. Accessed October 4, 2019. <https://www.longtermplan.nhs.uk/publication/nhs-long-term-plan/>
30. Kaplan A, Levitz S, Petrasko K. The role of spirometry in the management of obstructive airways disease: How pharmacists should get involved. *Can Pharm J (Ott)*. 2017;150(4):229-232. doi:10.1177/171516351714488

# Ask an OPA Pharmacist: How Long Can Patients be on Liraglutide for Weight Loss?

## Page 21

1. Davies, MJ, Bergenstal, R, Bode, B. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. JAMA. August 2015, 413(7):687-699
2. J van Can, B Sloth, CB Jensen, A Flint, EE Blaak and WHM Saris. Effects of the once daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International Journal of Obesity (Lond). 2014 Jun;38(6):784-93
3. Health Canada. Drug Product Database Search [Internet] cited 2019 Nov 20. Saxenda Product Monograph revised 2017 July 12 Available from: [https://pdf.hres.ca/dpd\\_pm/00040084.PDF](https://pdf.hres.ca/dpd_pm/00040084.PDF).
4. Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet [Internet]. 2017 Feb [cited 2019 Nov 20];389: 1399-409. Available from [https://doi.org/10.1016/S0140-6736\(17\)30069-7](https://doi.org/10.1016/S0140-6736(17)30069-7).

# Ask OPA Pharmacy Technicians

## Page 22

1. COVID-19 Guidance for the Health Sector. Ministry of Health. Accessed July 10, 2020. <[http://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/2019\\_guidance.aspx](http://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/2019_guidance.aspx)>
2. Resources for Coronavirus. Ontario Pharmacists Association. Accessed July 10, 2020. <<https://www.opatoday.com/professional/resources/for-pharmacists/tools-and-forms/coronavirus-2>>
3. Notice: Ontario Drug Benefit (ODB) Program Changes and Guidance for Dispensers during the COVID-19 Public Health Emergency. Ministry of Health. Accessed July 10, 2020. <<https://www.oha.com/Bulletins/EO%20Notice%20-%20ODB%20Program%20Changes%20and%20Guidance%20for%20Dispensers%20during%20the%20COVID-19%20Public%20Health%20Emergency%20-%20FINAL%20ENG.pdf>>
4. Canadian Pharmacists Association warns against stockpiling medication in response to COVID-19. Canadian Pharmacists Association. Accessed July 10, 2020. <<https://www.pharmacists.ca/news-events/news/canadian-pharmacists-association-warns-against-stockpiling-medication-in-response-to-covid-19/>>
5. Drug and medical device supply monitoring. Coronavirus disease (COVID-19): Canada's response. Government of Canada. Accessed July 10, 2020. <<https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/canadas-reponse.html?topic=Canada%27s+response&response=Drug+and+medical+device+supply+monitoring#dm>>
6. Drug shortages homepage. Drug Shortages Canada. Accessed July 10, 2020. <<https://www.drugshortagescanada.ca/>>
7. COVID-19 Pandemic A Pharmacist's Guide to Pandemic Preparedness. Ontario Pharmacists Association. Accessed July 10, 2020. <[https://www.opatoday.com/Media/Default/Default/2020-03-17%20OPA%20GUIDE%20FOR%20PANDEMIC%20PREPAREDNESS\\_FINAL.pdf](https://www.opatoday.com/Media/Default/Default/2020-03-17%20OPA%20GUIDE%20FOR%20PANDEMIC%20PREPAREDNESS_FINAL.pdf)>
8. Ontario Lifting 30-Day Supply Limit on Prescriptions. Ontario. Accessed July 10, 2020. <<https://news.ontario.ca/mohltc/en/2020/06/ontario-lifting-30-day-supply-limit-on-prescriptions.html>>